Which of the following medications is subject to a Risk Evaluation and Mitigation Strategy (REMS) program because current patients should avoid becoming pregnant?

Rationale

Mycophenolate is subject to a Risk Evaluation and Mitigation Strategy (REMS) program because current patients should avoid becoming pregnant.

Mycophenolate is known to cause serious birth defects if taken during pregnancy, which is why it is included in the REMS program to ensure that women of childbearing age are adequately informed and protected from the risks associated with its use.

A (Sertraline) YOUR ANSWER

Sertraline is an antidepressant that is generally considered safe for use during pregnancy, although it may have some risks. It does not fall under a REMS program related to pregnancy because the risks are not as severe as those associated with mycophenolate.

B (Ondansetron) YOUR ANSWER

Ondansetron is an anti-nausea medication that has been used during pregnancy, particularly for hyperemesis gravidarum. Although there are some considerations regarding its use, it is not subject to a REMS program focused on pregnancy, as the potential risks do not warrant the same level of precaution as mycophenolate.

C (Montelukast) YOUR ANSWER

Montelukast is a medication used to manage asthma and allergies and has not been associated with significant risks during pregnancy. Therefore, it does not require a REMS program aimed at preventing pregnancy-related complications, unlike mycophenolate.

D (Mycophenolate) CORRECT

Mycophenolate is specifically contraindicated in pregnancy due to its known teratogenic effects, which can lead to serious birth defects. This necessitates the implementation of a REMS program to ensure that patients are aware of these risks and take appropriate precautions.

Conclusion

Mycophenolate's inclusion in a REMS program is critical due to its potential to cause severe birth defects if taken during pregnancy. In contrast, other medications listed, such as sertraline, ondansetron, and montelukast, do not carry the same level of risk and thus do not require a REMS program focused on pregnancy prevention. This distinction underscores the importance of patient education and safety measures in the management of medications with serious reproductive risks.

Which of the following medications is subject to a Risk Evaluation and Mitigation Strategy (REMS) program because current patients should avoid becoming pregnant?

Mycophenolate is subject to a Risk Evaluation and Mitigation Strategy (REMS) program because current patients should avoid becoming pregnant.

Related Questions

Related Quizzes

How familiar were you with this question?

Report an Issue

Rate this Practice Test